Abstract
Antibody Response to the Coronavirus Disease 2019 Ad26.COV2.S Vaccine Among Maintenance Dialysis Patients
Highlights
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article
Antibody Response Among Maintenance Dialysis Patients to the COVID-19 Ad26.COV2.S Vaccine To the Editor: This quality improvement project aimed to determine whether dialysis patients on various dialysis modalities, vaccinated in dialysis clinics or the community, differed in antibody response to COVID-19 Ad26.COV2.S vaccine
Journal Pre-proof Ad26.COV2.S in twenty dialysis clinics selected in order to maximize patients with various dialysis modalities and vaccination setting, were eligible
Summary
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. Journal Pre-proof Ad26.COV2.S in twenty dialysis clinics selected in order to maximize patients with various dialysis modalities and vaccination setting, were eligible. Antibody levels by group are presented for patients without and with COVID-19 history, in figures 1 and 2, respectively.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
